Joshua Resnick Increases Stake in PepGen Inc.
Joshua Resnick recently purchased 34,000 shares of PepGen Inc., reflecting continued interest in the biotechnology firm.
Key Points
- On June 18, 2026, Joshua Resnick bought 34,000 shares of PepGen Inc. (PEPG) as part of insider transactions.
- PepGen Inc. shares traded at $1.79 on Tuesday, with a market cap of approximately $126.6 million and a 52-week high of $7.80.
- Analysts have a strong buy consensus on PepGen Inc. with a target mean price of $10.25 and recent price targets from Craig-Hallum and Oppenheimer.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Joshua Resnick recently increased his holdings in PepGen Inc. (NasdaqGS: PEPG) by purchasing 34,000 shares on June 18, 2026. This transaction was not part of a pre-planned trading program. The details of the purchase, such as the price per share, weren't disclosed.
Insider Buying and Selling at PepGen Inc.
In addition to Joshua Resnick, several other insiders at PepGen Inc. made similar moves on June 18, 2026. Heidi Henson, Laurie Keating, Lisa Wyman, Habib Dable, and Mitchell Finer each bought 34,000 shares. These transactions reflect a unified show of confidence in the company's future.
Other Institutional Activity in PepGen Inc.
Among PepGen's institutional investors, Commodore Capital LP increased its holdings by 1,075,000 shares, reaching a total of 4,475,000 shares valued at about $7.92 million. Laurion Capital Management LP also boosted its position by 698,722 shares to a total of 2,750,855 shares worth approximately $4.87 million. Meanwhile, Millennium Management LLC made a significant move by adding 1,881,200 shares, resulting in a 950.4% increase to 2,079,143 shares, valued at $3.68 million.
PepGen Inc. Stock Down 40.6%
Shares of PepGen Inc. traded at $1.79 on Tuesday. The biotechnology company, with a market cap of about $126.6 million, has experienced a 52-week range from a low of $1.01 to a high of $7.80. It has a forward P/E ratio that isn't meaningful as the company is not currently profitable. PepGen's stock also has a beta of 1.927, indicating higher volatility compared to the overall market.
$PEPG stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been active with their assessments of PepGen Inc. On June 16, 2026, Craig-Hallum initiated coverage with a buy rating and an $11.00 price target. Earlier, on February 25, 2026, Oppenheimer also initiated with a buy rating, setting a target of $15.00. The consensus among analysts is a strong buy, with a mean price target of $10.25 across eight opinions.
About PepGen Inc.
PepGen Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company is currently advancing its PGN-EDODM1 and FREEDOM2-DM1 programs, both in Phase 2 clinical trials for myotonic dystrophy type 1. Led by CEO Dr. James G. McArthur, PepGen is committed to addressing unmet needs in the healthcare sector.
Bottom Line
Joshua Resnick's recent purchase of PepGen shares highlights continued interest in the company's potential within the biotechnology space. While insider transactions can signal confidence, they are just one piece of the puzzle for investors to consider. As always, it's important to remember that 13F filings and insider buys are backward-looking and may not reflect current positions. PepGen's ongoing clinical trials and analyst ratings will be key areas to watch moving forward.
Get PepGen Inc. alerts
New 13F filings, insider trades, and analyst moves on $PEPG, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.